Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer of early cancer tests, has noted that the Company’s North American licensing partner, Cizzle Bio Inc, has today announced it has executed a strategic laboratory agreement with BioBridge Global, a San Antonio-based healthcare services organisation with expertise in laboratory medicine, biomanufacturing, blood banking and translational science. This is the second commercial agreement with a clinical laboratory group as BIO rolls out its implementation programme to deliver the Company’s proprietary CIZ1B Biomarker Blood Test for Lung Cancer
Under the terms of the agreement, BBG Advanced Therapies, a subsidiary of nonprofit BBG, will serve as a Clinical Laboratory Improvement Amendments certified laboratory partner offering the Test for lung cancer to licensed healthcare providers across South Texas, USA.
Because the Test is a laboratory-developed test (LDT), each CLIA-certified laboratory performing the assay must complete independent validation to verify analytical performance and meet rigorous quality standards. BBG Advanced Therapies has initiated this validation process and, upon completion, will become an additional CLIA-certified laboratory offering the Test to licensed healthcare providers in South Texas.
The agreement is designed to advance BIO’s broader commercialisation strategy to expand national access to a high-impact, minimally invasive biomarker blood test in regions facing a significant lung cancer burden and health disparities. This collaboration is part of BIO’s phased national strategy to build a network of high-quality laboratory partners offering the Test to licensed healthcare providers across the United States.
On 16 June 2026, the Company announced the Test had successfully completed laboratory validation and is approved for use under CLIA at OmniHealth Diagnostics. With initial sales under way at OmniHealth, BIO is rapidly adding to its portfolio of additional CLIA-certified laboratory partners across the United States.
Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said:
“After decades of research and development, the Company’s CIZ1B biomarker test for early-stage lung cancer is now benefiting patients with initial sales having commenced at OmniHealth. Our licensing partner, BIO, is addressing the challenge of rolling out with selected clinical laboratories to enable the Test to be delivered at scale not just in Texas, but across all areas of the U.S., Canada and the Caribbean.”
Commenting, Bill Behnke, founder and CEO of BIO, said:
“Early detection can dramatically improve outcomes, yet too many patients are diagnosed after lung cancer has progressed. Our collaboration with BBG represents an important step toward expanding access to the CIZ1B Biomarker Blood Test across South Texas and advancing our commitment to help healthcare providers detect lung cancer earlier, when patients may have more treatment options.”
Marty Landon, Chief Executive Officer of BioBridge Global, said:
“Collaborating with Cizzle Bio brings together their innovative biomarker technology with BBG’s expertise in laboratory operations, quality systems and regulatory compliance. By combining our strengths, we’re helping expand access to advanced early detection cancer screening while ensuring health care providers have confidence in the quality and reliability of the testing they offer their patients.”
Adrienne Mendoza, Chief Operating Officer of BioBridge Global, added:
“Innovation only changes lives when patients can access it. This collaboration reflects BBG’s commitment to working alongside pioneering organizations like Cizzle Bio to help translate scientific advances into real-world healthcare solutions. Together, we’re expanding access to an innovative test that has the potential to improve patient care and strengthen the health of the communities we serve.”
